Qiagen fails to get Zymo's US antitrust counterclaims dismissed in patent suit
MLex Summary: Qiagen must face US claims from Zymo Research accusing it of misusing its patents over technology that allows researchers to extract nucleic acids to stifle competition, a federal judge...To view the full article, register now.
Already a subscriber? Click here to view full article